LENZ Therapeutics Statistics
Total Valuation
LENZ has a market cap or net worth of $1.01 billion. The enterprise value is $812.18 million.
Important Dates
The last earnings date was Wednesday, November 6, 2024, before market open.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LENZ has 27.50 million shares outstanding. The number of shares has increased by 486.94% in one year.
| Current Share Class | 27.50M |
| Shares Outstanding | 27.50M |
| Shares Change (YoY) | +486.94% |
| Shares Change (QoQ) | +6.11% |
| Owned by Insiders (%) | 2.79% |
| Owned by Institutions (%) | 41.03% |
| Float | 12.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.77 |
| P/TBV Ratio | 4.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 28.63, with a Debt / Equity ratio of 0.01.
| Current Ratio | 28.63 |
| Quick Ratio | 28.16 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -41.90% and return on invested capital (ROIC) is -29.25%.
| Return on Equity (ROE) | -41.90% |
| Return on Assets (ROA) | -27.03% |
| Return on Capital (ROIC) | -29.25% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -179,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +131.48% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +131.48% |
| 50-Day Moving Average | 29.08 |
| 200-Day Moving Average | 22.38 |
| Relative Strength Index (RSI) | 62.56 |
| Average Volume (20 Days) | 147,812 |
Short Selling Information
The latest short interest is 2.18 million, so 7.94% of the outstanding shares have been sold short.
| Short Interest | 2.18M |
| Short Previous Month | 2.07M |
| Short % of Shares Out | 7.94% |
| Short % of Float | 17.45% |
| Short Ratio (days to cover) | 17.72 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -68.37M |
| Pretax Income | -117.37M |
| Net Income | -60.81M |
| EBITDA | -68.34M |
| EBIT | -68.37M |
| Earnings Per Share (EPS) | -$2.69 |
Full Income StatementBalance Sheet
The company has $217.11 million in cash and $1.58 million in debt, giving a net cash position of $215.53 million or $7.84 per share.
| Cash & Cash Equivalents | 217.11M |
| Total Debt | 1.58M |
| Net Cash | 215.53M |
| Net Cash Per Share | $7.84 |
| Equity (Book Value) | 215.28M |
| Book Value Per Share | 7.83 |
| Working Capital | 212.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$71.28 million and capital expenditures -$319,000, giving a free cash flow of -$71.60 million.
| Operating Cash Flow | -71.28M |
| Capital Expenditures | -319,000 |
| Free Cash Flow | -71.60M |
| FCF Per Share | -$2.60 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |